Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Teva Pharmaceutical Industries's quarterly Total Liabilities
declined
from Dec. 2025 (R$179,132.45 Mil) to Mar. 2026 (R$166,343.12 Mil) and
declined
from Mar. 2026 (R$166,343.12 Mil) to Jun. 2026 (R$164,483.61 Mil).
Teva Pharmaceutical Industries's annual Total Liabilities
increased
from Dec. 2023 (R$173,222.63 Mil) to Dec. 2024 (R$205,030.21 Mil) but then
declined
from Dec. 2024 (R$205,030.21 Mil) to Dec. 2025 (R$179,132.45 Mil).
Teva Pharmaceutical Industries Total Liabilities Related Terms
Teva Pharmaceutical Industries Total Liabilities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Teva Pharmaceutical Industries Total Liabilities Chart
Teva Pharmaceutical Industries Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of R$164,484 Mil mean?
Teva Pharmaceutical Industries (BSP:T1EV34) has a Total Liabilities of R$164,484 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Teva Pharmaceutical Industries and its competitors.
Is Teva Pharmaceutical Industries' Total Liabilities too high?
Teva Pharmaceutical Industries' current Total Liabilities is R$164,484 Mil. Overall, Teva Pharmaceutical Industries has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Total Liabilities compare to ZTS and UTHR?
Teva Pharmaceutical Industries' Total Liabilities of R$164,484 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Teva Pharmaceutical Industries and its competitors. Teva Pharmaceutical Industries's current Total Liabilities is R$164,484 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (BSP:T1EV34) is currently considered Significantly Overvalued. The stock's GF Value™ is R$50.50, compared to a current price of R$78.80 — trading 56% above its estimated fair value. The current Total Liabilities is R$164,484 Mil. Teva Pharmaceutical Industries' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Teva Pharmaceutical Industries (BSP:T1EV34), the current Total Liabilities is R$164,484 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Teva Pharmaceutical Industries (BSP:T1EV34) Overvalued in 2026?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued.
The current stock price of R$78.80 is trading 56% above its estimated GF Value™ of R$50.50.
GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.
Key valuation signals for BSP:T1EV34:
Total Liabilities: R$164,484 Mil
GF Value™: R$50.50 vs. price of R$78.80 (56% above fair value)
No single metric tells the full story. See the BSP:T1EV34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Teva Pharmaceutical Industries Business Description
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
36GF Score
Get the complete analysis for BSP:T1EV34
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:T1EV34 has been successfully added to your 
